Tada

I hope there is clear communication of what is happeneing in terms of results that will be understandable to people like me with very little science background. How may are living longer? What types of patients are living longer...what markers distinguish them? If they have a specific profile how big might the market be? What characterizes patient profiles for those patients where zen3694 does not work?

Perhaps there actually is some merit in Don's apparent exuberance when he talked to GAC about Zenith being sold in the next 2 to 3 months. One month has going by since that discussion at B & B so that leaves June and July for the sale. I've expressed my skepticism but I hope I am wrong.

One think for sure we need clarification (I mean clear language) on what is emerging from the trials.

Cheers

Toinv